NewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 03 2025
0mins
Source: SeekingAlpha
Phase III data (BROADWAY) Showed great efficacy on LDL lowering and safety, no different from placebo. Demonstrated a 21% 4-point MACE reduction.
Pooled MACE data (BROOKLYN and BROADWAY) Showed more than 21% relative risk reduction for the 4-point MACE.
Cash position Entered the year in a very strong position cash-wise after raising financing off the Phase III data.
EMA approval filing Filed in Europe for EMA approval, accepted about 2 weeks ago.
Biomarker improvement in ApoE4 patients Lowered Ptau 217, an excellent biomarker of amyloid pathology in the brain, over 12 months. Greater reduction observed in ApoE4 homozygotes (E4/E4).
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on NAMS
Wall Street analysts forecast NAMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAMS is 48.63 USD with a low forecast of 37.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 31.440
Low
37.00
Averages
48.63
High
60.00
Current: 31.440
Low
37.00
Averages
48.63
High
60.00
About NAMS
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NAMS Options Analysis: $30 Put Contract Offers Attractive Yield Boost
- Put Option Appeal: The $30.00 put option for NAMS has a current bid of 20 cents, and if an investor sells this contract, they commit to buying shares at $30.00, effectively lowering their cost basis to $29.80, which is about a 6% discount from the current price of $31.77, making it attractive for those looking to enter at a lower price.
- Yield Potential: Should the put option expire worthless, it would yield a 0.67% return on cash commitment, or an annualized yield of 3.86%, referred to as YieldBoost, highlighting the potential profitability of this contract.
- Call Option Returns: The $35.00 call option has a current bid of 40 cents, and if an investor buys shares at $31.77 and sells this call, they could achieve a total return of 11.43% if the stock is called away at expiration, showcasing the potential upside of this strategy.
- Risk Assessment: Current analytics suggest a 65% chance that the $30 put option will expire worthless, while the $35 call option has a 56% chance of doing the same, indicating that investors should carefully weigh the risks and rewards when selecting their options strategies.
Continue Reading
NewAmsterdam Pharma Expects EMA Approval for Obicetrapib in 2H26
- Clinical Trial Progress: NewAmsterdam Pharma has enrolled its first patient in the RUBENS Phase 3 trial initiated in December 2025, which is expected to provide new treatment options for patients with metabolic syndrome, thereby enhancing the company's competitive position in the cardiovascular disease market.
- Strong Financial Position: As of December 31, 2025, NewAmsterdam reported a cash, cash equivalents, and marketable securities balance of approximately $729 million, which is sufficient to fund operations through the anticipated readout of the PREVAIL trial, ensuring future commercialization potential.
- Regulatory Advancements: The company is advancing its EMA applications for obicetrapib and its fixed-dose combination with Menarini, with an expected approval decision in 2H26, which will lay the groundwork for commercialization in the European market.
- Clear Strategic Goals: NewAmsterdam plans to initiate a clinical trial for Alzheimer's disease in 2026, further expanding the indications for obicetrapib, demonstrating the company's strategic positioning in both cardiovascular and neurodegenerative disease sectors.
Continue Reading